Takeda Files Japan Marketing Application For Darvadstrocel In Crohn's Disease

  • Takeda Pharmaceutical Co Ltd (NYSE: TAK) has applied to the Japanese regulatory authority seeking approval for Darvadstrocel (Cx601) to treat complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease. Darvadstrocel received an orphan drug designation in Japan in March 2019.
  • The application filing included data from two trials, the Japanese Study Darvadstrocel-3002 and the ADMIRE-CD trial, conducted in Europe and Israel. Takeda will present the data from Darvadstrocel-3002 at a scientific meeting soon. 
  • Darvadstrocel is approved in the European Union, Israel, Switzerland, and the U.K. to treat complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease when fistulas have shown an inadequate response to at least one conventional or biologic therapy.
  • Price Action: TAK shares closed 1.7% higher at $17.71 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsFDAGeneralCrohn's Disease
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!